Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.76 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8344736 | 1.00 | ELANE (0.76) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL8345606 | 0.93 | ELANE (0.83) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL8344866 | 0.91 | ELANE (0.79) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL8344863 | 0.90 | ELANE (0.83) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL14760555 | 0.90 | ELANE (0.83) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL8281825 | 0.89 | ELANE (0.72) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL392232 | 0.87 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL1764353 | 0.87 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL3482731 | 0.87 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL3482210 | 0.85 | ELANE (0.81) | ELANECYP2C9ADRB1HTR1AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687510-B2 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER HEALTHCARE AG (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687510-B2 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER HEALTHCARE AG (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687510-B2 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER HEALTHCARE AG (DE) | 2010-03-30 | — | — | US | disclosed |
| US-20060160801-A1 | Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160801-A1 | Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | PTGIS, PTGIR, FPR1 | ELANE 59/4885CYP2C9 4171/4885ADRB1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.